Refine by
Patient Insurance Coverage Support Articles & Analysis: Older
99 news found
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an ...
ByTempus
We are thrilled to welcome KEMP Hospice to the growing community of amazing charities we work with across the UK. We are proud to provide the charity with our affordable and adaptable software solutions that support the outstanding care they provide to families and people living with life-limiting illnesses across their ...
We are delighted to welcome Saint Catherine’s Hospice Scarborough to the growing community of amazing hospice charities we work with across the UK. We are proud to provide Saint Catherine’s with our affordable and adaptable software solutions that support the outstanding care they provide to people with life-limiting ...
We are delighted to welcome St Luke’s Hospice to the growing community of amazing hospice charities we work with across the UK. We are proud to provide St Luke’s with our affordable and adaptable software solutions that support the outstanding care they provide to people living with life-limiting illnesses. ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
Stemline ARC, a patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identifying potential financial assistance options. For more information, ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that preliminary results from the ongoing Phase 1/2 study (NCT04104776) of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients. Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications ...
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
Toro Equipment supports the 22q11 Syndrome Association, a non-profit organisation that aims to be a link between families, professionals and organisations involved in the care of people with 22q11 deletion and 22q11 duplication, in order to improve their quality of life and social integration. The aims of the 22q11 Syndrome Association are: To defend the interests of those affected by 22q11 ...
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The ...
ByxCures
The National Institutes of Health (NIH) has awarded Berkshire Biomedical Awarded $266,000 to support continued development of an automated, at-home methadone administration system. Called the COPA system, the proprietary, hand-held drug dispensing device is meant to provide at-home methadone administration as part of treatment for opioid use disorder (OUD). The system delivers the liquid ...
Berkshire Biomedical Corporation ("Berkshire" or "the Company"), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health's (NIH) National ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization. The approval is based on data from the Phase III VOYAGER PAD trial. This study demonstrated a positive ...
ByBayer AG
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an ...
PatientPoint today announced that it will be supporting the Susan G. Komen®Stand for H.E.R—a Health Equity Revolution program by bringing point-of-care breast health resources to patients and healthcare providers in U.S. metropolitan areas where breast cancer mortality gaps are greatest between Black and white women. Now through the end of 2022, PatientPoint will promote Komen content ...